Research comparison
CJC-1295 vs ipamorelin
CJC-1295 and ipamorelin are usually discussed as a pair because they act on the same physiological axis through two different doors — and because they are widely sold as a premixed combination. Comparing them properly means being precise about which door each opens, and about what the combination literature does not contain.
This page compares the research profiles of both compounds and of the combination itself. The profiles carry the citations; nothing here is a claim about effects in people.
| CJC-1295 with DAC | Ipamorelin | CJC-1295 and ipamorelin combination | |
|---|---|---|---|
| Category | Peptide analogue | Peptide | Combination |
| Highest evidence | Early human — evidence level 3 of 4: Early human evidence Findings come from small, early-phase or observational human studies. These are typically short, sparsely replicated, and designed to examine tolerability or signal rather than to establish effect. | Early human — evidence level 3 of 4: Early human evidence Findings come from small, early-phase or observational human studies. These are typically short, sparsely replicated, and designed to examine tolerability or signal rather than to establish effect. | In vitro — evidence level 1 of 4: In-vitro evidence Findings come from cells, tissues or biochemical systems studied outside a living organism. Such findings describe what a compound can do in a controlled system, not what it does in a person. |
| UK regulatory status | Experimental — UK regulatory status: Experimental — not authorised for human use in the UK A compound appearing in research literature that holds no UK authorisation for human use in any indication. | Experimental — UK regulatory status: Experimental — not authorised for human use in the UK A compound appearing in research literature that holds no UK authorisation for human use in any indication. | Experimental — UK regulatory status: Experimental — not authorised for human use in the UK A compound appearing in research literature that holds no UK authorisation for human use in any indication. |
| Research areas | Pituitary endocrinology | Pituitary endocrinology; Gastrointestinal motility models | Pituitary endocrinology; Combination pharmacology |
| Verified citations | 1 | 2 | 2 |
CJC-1295 with DAC
A growth hormone-releasing hormone analogue carrying an albumin-binding moiety that extends its half-life to several days.
CJC-1295 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone, modified to resist enzymatic degradation, and proposed to act as an agonist at the pituitary receptor for that hormone. The form carrying a drug affinity complex additionally binds covalently to serum albumin, which extends the measured half-life to roughly six to eight days. That extended exposure is the compound’s defining property and also the principal source of uncertainty about it.
Ipamorelin
A synthetic pentapeptide growth hormone secretagogue whose one controlled human trial did not meet its endpoint.
Ipamorelin is a synthetic pentapeptide acting as an agonist at the growth hormone secretagogue receptor, the receptor for the endogenous hormone ghrelin. Binding is proposed to stimulate release of growth hormone from the anterior pituitary. In the originating pharmacology it released growth hormone from primary rat pituitary cells with potency similar to GHRP-6 but, unlike other secretagogues tested, did not significantly raise corticotropin or cortisol. Any downstream effect on body composition in humans is inferred from the growth hormone axis rather than demonstrated.
CJC-1295 and ipamorelin combination
A two-peptide mixture with no combination data, in which the identity of one component is usually unstated.
This pairs a growth hormone-releasing hormone receptor agonist with a selective ghrelin receptor agonist, on the rationale that stimulating two distinct upstream receptors amplifies pituitary output more than either alone. The underlying physiological principle derives from studies of other molecules in those two classes, not from this pair. The combination’s net effect on pulse amplitude, IGF-1, cortisol, prolactin and glucose handling has never been characterised in humans.
How the research differs
Two different receptors in one axis
CJC-1295 is an analogue of growth hormone-releasing hormone, proposed to act at the pituitary GHRH receptor; the with-DAC form adds an albumin-binding complex that extends its half-life to several days. Ipamorelin is a pentapeptide agonist at the growth hormone secretagogue receptor — the ghrelin receptor. Same axis, different receptors, different molecules entirely.
What the pairing rationale actually is
The combination rationale is that stimulating two distinct upstream receptors amplifies pituitary output more than either alone — a principle derived from studies of other molecules acting on the same receptors. As the combination profile records, there is no controlled data on this specific two-peptide mixture, and commercial listings frequently leave the identity of the CJC-1295 component (with or without DAC) unstated.
The evidence is thinner than the popularity
Ipamorelin’s one controlled human trial did not meet its endpoint — its profile says so in its first sentence. CJC-1295 with DAC has early human pharmacology data. The combination as sold has none. All three profiles grade this explicitly, which is precisely why they are worth reading side by side rather than through the pairing’s reputation.